Dr Matthew Krebs is Clinical Senior Lecturer in Experimental Cancer Medicine at The University of Manchester and Honorary Consultant in Medical Oncology at The Christie NHS Foundation Trust, Manchester, UK.
Dr Krebs’ expertise is in early-phase clinical trials with focus on drug development for lung cancer and precision medicine. His research focuses on personalised medicine, circulating biomarkers and clinical application of novel biomarkers in guiding treatment selection. He has extensive experience in early phase clinical trials involving first in-human therapies and novel combinations and served as Principal or Chief Investigator in over 45 phase I trials, whilst acting as co-investigator in over 80 studies spanning a wide range of novel therapies and indications. Dr Krebs has authorship in more than 50 peer-reviewed publications and over 100 conference abstracts, with writings in non-small lung cancer including topics such as: novel targeted therapies, tyrosine kinase inhibitors, immuno-oncology and clinical utility of circulating biomarkers.
Dr Krebs is Clinical Lead for Precision Medicine within The Christie NHS Foundation Trust’s Experimental Cancer Medicine Team, Chief Investigator of the TARGET National Precision Medicine Program, and Chair of the National ctDNA Molecular Tumour Board. He works within the Cancer Research UK Manchester-UCL Lung Cancer Centre of Excellence and serves as Cancer Genomics Clinical Lead within the North West Genomics Laboratory Hub in the UK.
EM-124387 - Date of preparation: February 2023